Skip to main content
Evidence Based Longevity (EBL)Check what I take
← All protocols
C

Protocol

Blueberries (1 cup a day) for blood vessel function

In a 6-month randomized trial of 115 adults with metabolic syndrome, 1 cup of blueberries a day improved flow-mediated dilation by 1.45% and one measure of arterial stiffness (augmentation index), while insulin resistance (the primary outcome), pulse wave velocity, blood pressure and nitric oxide were unaffected and half a cup did nothing.

Grade C: human trials exist, but they are small, mixed or not yet repeated. This is not a finding that it does not work. How to read a grade →

Compare this record with another, side by side →

At a glance

In plain words

In a six-month trial, adults with metabolic syndrome who ate the equal of a cup of blueberries a day had better blood vessel function. Their insulin resistance, the main thing the trial set out to test, did not change, and neither did blood pressure. Half a cup did nothing. The trial used freeze-dried blueberry powder.

The letter, taken apart
What was measured
Flow-mediated dilation after 6 months.
How big
Flow-mediated dilation improved by 1.45% with 1 cup a day.Read from the summary of PMID PubMed ID: the permanent number the US National Library of Medicine gives a published paper. Each one links to that paper's record on PubMed. 31136659.
Who it applies to
Adults with metabolic syndrome, freeze-dried powder, 6 months.
Safety
None reported.
The record in one view
Compared with
A matched placebo An inactive substitute made to look like the real treatment, so participants cannot tell which one they received. powder.
Certainty
Grade C, resting on: One 6-month double-blind Neither the participants nor the people assessing them know who received the real treatment until the trial ends. randomized trial and supporting short trials.
What would change this grade
Could rise to B with: Randomized trial of blueberries. Who: Adults with metabolic syndrome or hypertension. Measured: Blood pressure or HbA1c A blood test that reflects average blood sugar over the previous two to three months.. Length: At least 6 months.
Cost
No price recorded yet.
Sources
2 studies cited on this record, listed under Sources.
For clinicians
A one-page summary of this record that prints with a clinician's name and practice, folds to a plain-language patient handout, and gives a chart note to paste into the patient record: Printable summary and chart note.
Food
CSurrogate biomarker Grade C

In a 6-month randomized trial of 115 adults with metabolic syndrome, 1 cup of blueberries a day improved flow-mediated dilation by 1.45% and one measure of arterial stiffness (augmentation index), while insulin resistance (the primary outcome), pulse wave velocity, blood pressure and nitric oxide were unaffected and half a cup did nothing. FMD is not a validated stand-in for cardiovascular events under EBL's rule, so the letter is C.

Why this letter

Why this gradeGrade C, small or unreplicated trials. The reasoning, and what the grade does not cover.
Why this grade

Grade C on blood vessel function. A 6-month double-blind trial found FMD 1.45% higher with 1 cup of blueberries a day (Curtis et al., 2019; PMID 31136659), with supporting short trials in healthy adults (Rodriguez-Mateos et al., 2019; PMID 30772905).

WHY NOT Bunder EBL's standing rule (October 2026, the MitoQ ruling), FMD is a mechanistically and prognostically relevant measure but not a validated surrogate for cardiovascular events, so FMD alone caps at C; the trial's primary outcome, insulin resistance, was unchanged.

WHAT THIS GRADE DOES NOT COVERfresh berries as opposed to the freeze-dried powder tested, half a cup a day, which had no effect, and heart attacks or strokes, which were not measured.

A grade describes the human evidence for a named use. It is not advice, and it is not a judgment on any individual prescription. How the letters are decided →

Who responds: this record's trial reading reports no subgroup that identifies who responds.

Evidence notes: randomized trial

Endpoint The outcome a trial measures to decide whether the treatment worked, such as heart attacks, blood pressure or a symptom score. graded: Flow-mediated dilation (surrogate)

Last reviewed: November 2026

Evidence wanted

The trial that would change this grade.

DesignRandomized trial of blueberries
PopulationAdults with metabolic syndrome or hypertension
EndpointBlood pressure or HbA1c
DurationAt least 6 months

A positive trial of this shape, supported by further trials, would move this entry to B.

Why the current trials fall short

A qualifying stand-in such as blood pressure moving would allow a B.

Clinical trials

ClinicalTrials.gov, the public registry run by the U.S. National Library of Medicine, lists studies that are recruiting volunteers. The link below searches it for Blueberry Plants among studies recruiting now. EBL has no relationship with any listed study and receives no payment for this link.

Search recruiting studies of Blueberry Plants on ClinicalTrials.gov

Dose, form and timing

What to track

Not applicable; FMD needs specialist ultrasound.

Safety

Safety evidence, by strength

No safety data. Each caution on this record, sorted by what it rests on.

Documented in human studies
Cautions resting on what randomized trials or large studies found in people.

None recorded.

Suspected from case reports
Harms reported in individual patients or uncontrolled observations, not confirmed by a trial.

None recorded.

Mechanistic only
Cautions reasoned from how it works, with no human harm data behind them.

None recorded.

Population cautions
Groups in whom it has not been studied, so its safety there is unknown.

None recorded.

No safety data

No safety data: EBL has found no trial or report of harm for this record. That is an absence of evidence, not a finding of safety.

Grade history

How this letter has changedLatest: No. 460 · November 2026 · First graded.
Grade history
No. 460 · November 2026 · First graded
Blueberries (1 cup a day) for blood vessel function enters the food section: Grade C

New record in the food section. In a 6-month randomized trial of 115 adults with metabolic syndrome, 1 cup of blueberries a day improved flow-mediated dilation by 1.45% and one measure of arterial stiffness (augmentation index), while insulin resistance (the primary outcome), pulse wave velocity, blood pressure and nitric oxide were unaffected and half a cup did nothing. FMD is not a validated stand-in for cardiovascular events under EBL's rule, so the letter is C.PMID 31136659 PMID 30772905

Every change to a letter on this site is dated and published. The full evidence log →

Sources

How this record was checked
Citations
Every paper cited on this page is matched to its PubMed record on every build.
Retractions
None of these papers is retracted or under a journal expression of concern. PubMed is checked again on every build.
Read against the papers
November 2026. By a language model (AI-assisted reading), not yet reviewed by a clinician.
Outside review
Not yet done. No reviewer outside EBL has checked this record.

What each of these checks can and cannot show: evidence integrity.

The evidence, in fullTwo papers, each linked to its PubMed record.
The evidence

Curtis et al. (Am J Clin Nutr, 2019; PMID 31136659): double-blind placebo-controlled parallel trial, 115 adults with metabolic syndrome, 6 months, freeze-dried blueberry powder equal to 1 or half a cup a day; 1 cup improved FMD (+1.45%), augmentation index (-2.24%) and lipid status; insulin resistance, pulse wave velocity, blood pressure and NO unaffected; half a cup had no effect. Rodriguez-Mateos et al. (J Gerontol A, 2019; PMID 30772905): randomized trials in healthy adults linking anthocyanin metabolites to vascular benefits of blueberries.

How EBL searched for the trials (1 search)

The search that was run, what it returned, and what was left out and why, so the absence of evidence can be checked as well as its presence.

Searched PubMed in November 2026. 10 records screened, 2 eligible for the graded claim.
Query: (blueberr*[tiab]) AND randomized controlled trial[pt]
The 10 most recent of 111 records were screened by title; newer trials are short-term or test other outcomes (exercise, immune cells, brain health).
PubMed watch: does a new study change the grade? (nothing new)

No new paper matching the search behind this grade has been added to PubMed since November 2026.

Last run November 2026. A letter on EBL moves only after a logged review. A new paper never moves a letter by arriving: it is read, the answer is written here, and any change to the letter is published in the evidence log.

Who paid for these trials

For each trial behind a letter on this page, the funding its PubMed record lists. "No funder" means PubMed lists none, not that the trial had no funding.

  • Curtis et al., 2019, Am J Clin Nutr (PMID 31136659): PubMed lists funding from Biotechnology and Biological Sciences Research Council.

Disclosure

Educational use only · Not medical advice · EBL grades published human evidence and does not recommend treatment. Stopping a prescription is a decision for your physician.

Evidence Based Longevity, Inc. is owner-operated and edited by Arnold Sandlow, D.C., a California-licensed chiropractor. Evidence Based Longevity publishes in English only · Machine translations are not produced or reviewed by EBL for accuracy

© Evidence Based Longevity, Inc. All rights reserved

Medical disclaimer

These statements have not been evaluated by the Food and Drug Administration. Any grade on this page describes the strength of published human trial evidence in the populations studied. It is not a recommendation for any individual and is not medical advice. Starting, stopping or changing any supplement or medication is a decision for your physician.

Grades move when new trials publish. A free monthly email lists every grade EBL moved, with the reason and the trial behind it: the sign-up is on the Evidence Log →

Build 9b19d78, November 2026